Top Markets
Coin of the day
Pure Biologics Spólka Akcyjna Pure Biologics Spólka Akcyjna

Pure Biologics Spólka Akcyjna

PUR
株式のランク #33926
Pure Biologics Spólka Akcyjna operates as a biopharmaceutical enterprise,... Pure Biologics Spólka Akcyjna operates as a biopharmaceutical enterprise, concentrating its efforts on the discovery and development of novel biological pharmaceuticals and targeted, non-systemic treatments. The company's key therapeutic interests span immuno-oncology, various autoimmune conditions, and rare diseases. Its capabilities encompass the entire process for antibodies and aptamers, from their initial creation and purification to detailed analysis and characterization. Additionally, Pure Biologics is skilled in the design, development, and rigorous validation of diagnostic and research assays, while also advancing technology platforms for the precise selection of active therapeutic molecules. A significant offering is PureApta, a adaptable platform engineered for the in vitro selection of modified aptamers, suitable for both medical treatment and diagnostic applications. The firm is also actively pursuing the development of localized therapies aimed at assisting individuals afflicted by neurological autoimmune disorders, including conditions like neuromyelitis optica and myasthenia gravis. Founded in 2010, Pure Biologics Spólka Akcyjna is headquartered in Wroclaw, Poland.
株価
$0.8248572
最終同期: 2026-08-07
時価総額
$6.60M
変化(1日)
35.02%
変化(1年)
-54.35%
PL
取引 Pure Biologics Spólka Akcyjna (PUR)

カテゴリー

Pure Biologics Spólka Akcyjna(PUR)の利益
2026 時点の利益 TTM: 0
Pure Biologics Spólka Akcyjna の最新の財務報告によると、同社の現在の利益は 0 です。2026 年には 0 の利益を上げ、これは 2026 年の利益 0 と 同等 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Pure Biologics Spólka Akcyjna の利益の推移(2026 〜 2026)
各年末の利益
利益 変化
提供された日付のデータは十分ではありません。
同業他社の利益